Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited.

Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19.

Design, Setting, And Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin.

[Not Available].

Peritoneal carcinosis is considered to be a lethal disease with a very poor prognosis, however cytoreducticve surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) could represent a significant step forward in the therapy of peritoneal cranosis. In contrast to traditional surgical procedures and intravenous chemotherapy, which are moderately effective, CRS and HIPEC are new, personalised interventions, which can extend the lifespan of the patients in the majority of the cases. Moreover, there is a possibility to carry out definitive, curative therapy in a well-selected group of cases.